FIELD: medicine, biochemistry.
SUBSTANCE: invention relates to new compounds that are inhibitors of interleukin-1β-converting enzyme that are characterized by specific structural formulas. Also, invention relates to pharmaceutical compositions eliciting ability to inhibit interleukin-1β-converting enzymes, to method for treatment and prophylaxis of diseases taken among the group consisting of IL-1-mediated autoimmune, inflammatory, neurodegenerative diseases and to a method for selection of inhibitor of interleukin-1β-enzyme also.
EFFECT: valuable medicinal and biochemical properties of inhibitors.
50 cl, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEIKYN-1BETA CONVERTING ENZYME INHIBITORS | 1996 |
|
RU2249598C2 |
| 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5-HT3 MODULATORS | 2007 |
|
RU2448105C2 |
| CASPASE INHIBITORS | 1999 |
|
RU2274642C2 |
| DERIVATIVES OF TRIAZOLE OF AMIDE TYPE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR PROPHYLAXIS OR TREATMENT | 2001 |
|
RU2232761C2 |
| SUBSTITUTED TETRAHYDROPYRANSPIROPYRROLIDINONE AND TETRAHYDROPYRANSPIROPIPERIDINONE, BASED ON THEM PHARMACEUTICAL COMPOSITION AND APPLICATION FOR THERAPEUTIC PURPOSES | 2009 |
|
RU2519778C2 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| METHODS OF SYNTHESIS OF ESTEINASCIDINE, COMPOUNDS, INTERMEDIATE SUBSTANCE | 1997 |
|
RU2194709C2 |
| 2-ACYLAMINOPROPANOL GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | 2009 |
|
RU2578947C2 |
| HETEROCYCLIC COMPUNDS WITH HIGHER EFFICIENCY COUPLING WITH CHEMOKINE RECEPTOR | 2002 |
|
RU2325387C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
